Charles Schwab Investment Management Inc. Boosts Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

Charles Schwab Investment Management Inc. grew its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 1.9% during the third quarter, Holdings Channel reports. The institutional investor owned 315,092 shares of the company’s stock after buying an additional 5,966 shares during the period. Charles Schwab Investment Management Inc.’s holdings in SI-BONE were worth $4,405,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Rhumbline Advisers raised its stake in SI-BONE by 1.5% during the 2nd quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock valued at $768,000 after purchasing an additional 852 shares during the period. Arizona State Retirement System raised its stake in SI-BONE by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after purchasing an additional 903 shares during the period. The Manufacturers Life Insurance Company raised its stake in SI-BONE by 7.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company’s stock valued at $205,000 after purchasing an additional 1,105 shares during the period. Price T Rowe Associates Inc. MD raised its stake in SI-BONE by 7.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock valued at $336,000 after purchasing an additional 1,372 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in SI-BONE by 24.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after purchasing an additional 2,108 shares during the period. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on SIBN shares. Truist Financial lifted their target price on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of SI-BONE in a research note on Wednesday, November 20th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE presently has an average rating of “Buy” and a consensus price target of $23.00.

SI-BONE Stock Performance

NASDAQ:SIBN opened at $13.42 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $21.70. The stock’s 50 day simple moving average is $13.39 and its two-hundred day simple moving average is $14.09. The company has a market cap of $562.81 million, a price-to-earnings ratio of -14.59 and a beta of 1.20.

Insiders Place Their Bets

In other SI-BONE news, CEO Laura Francis sold 10,048 shares of SI-BONE stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.58, for a total value of $126,403.84. Following the sale, the chief executive officer now owns 482,875 shares of the company’s stock, valued at $6,074,567.50. The trade was a 2.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,937 shares of SI-BONE stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.60, for a total value of $49,606.20. Following the completion of the sale, the insider now directly owns 228,554 shares in the company, valued at approximately $2,879,780.40. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,679 shares of company stock valued at $276,439 in the last quarter. 3.90% of the stock is currently owned by insiders.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.